Ichnos Glenmark Innovation (IGI) has announced positive results from its Phase 1 clinical trial of ISB 2001, an experimental drug for relapsed/refractory multiple myeloma. The trial demonstrated a 75% overall response rate in patients, with favorable safety outcomes.
The data, collected through July 2024, revealed no dose-limiting toxicities and only one adverse event above Grade 2. Notably, no patients discontinued treatment during the study period. Among the 12 efficacy-evaluable patients, nine responded to the treatment, including one patient achieving MRD negative stringent complete response.
Mechanism of Action
ISB 2001 is designed as a first-in-class trispecific antibody. It simultaneously targets BCMA and CD38 on multiple myeloma cells and CD3 on T cells. The drug was created using IGI’s proprietary BEAT® technology platform.
Presentation at ASH
Dr. Hang Quach from the University of Melbourne is set to present the detailed findings at the American Society of Hematology (ASH) Annual Meeting in San Diego on December 9, 2024. IGI will also present data from another drug candidate, ISB 1442, during the conference’s poster session.
About IGI
Ichnos Glenmark Innovation (IGI) is a collaboration between Ichnos Sciences Inc. and Glenmark Pharmaceuticals Ltd., focusing on developing novel cancer treatments. The alliance leverages expertise in biologics and small molecules, with research facilities across the USA, Switzerland, and India. Over 150 scientists are involved in the pipeline of innovative therapies.
